Form 8-K - Current report:
SEC Accession No. 0001213900-24-098457
Filing Date
2024-11-14
Accepted
2024-11-14 16:15:46
Documents
14
Period of Report
2024-11-14
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0221102-8k_tffpharma.htm   iXBRL 8-K 35307
2 PRESS RELEASE DATED NOVEMBER 14, 2024 REGARDING THE DISSOLUTION OF THE COMPANY ea022110201ex99-1_tffpharma.htm EX-99.1 5018
  Complete submission text file 0001213900-24-098457.txt   220225

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tffp-20241114.xsd EX-101.SCH 3018
4 XBRL LABEL FILE tffp-20241114_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tffp-20241114_pre.xml EX-101.PRE 22361
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0221102-8k_tffpharma_htm.xml XML 3796
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

EIN.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 241462545
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)